Number and nature of drug interactions concerning antineoplastic drugs;Estimation du nombre et de la nature des interactions mé dicamenteuses concernant les médicaments anticancéreux

Bulletin du Cancer

Volumn 94, Issue 5, 2007, Pages 477-482

  Schwiertz, Vérane ^a   Bertin, Camille ^a   Henry, Agnès ^a   Charpiat, Bruno ^a  

^a CROIX ROUSSE HOSPITAL   (France)

Author keywords

Antineoplastic drugs; Database; Drug drug interactions

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; BLEOMYCIN; BUMETANIDE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EFAVIRENZ; ERLOTINIB; ETOPOSIDE; FLUCONAZOLE; FLUOROURACIL; IFOSFAMIDE; IMATINIB; IRINOTECAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PHENOBARBITAL; RITONAVIR; TIPRANAVIR; UNINDEXED DRUG; VALPROIC ACID; VINBLASTINE; VINCRISTINE; WARFARIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIINFECTIVE AGENT;

ARTICLE; CANCER PATIENT; DATA BASE; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG USE; HEALTH CARE PERSONNEL; HUMAN; LINGUISTICS; MEDICAL LITERATURE; PUBLICATION; DRUG INTERACTION; FACTUAL DATABASE; NEOPLASM; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; ANTINEOPLASTIC AGENTS; BIBLIOGRAPHY OF MEDICINE; DATABASES, FACTUAL; DRUG INTERACTIONS; HUMANS; NEOPLASMS; PERIODICALS;

EID: 34250662277     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0355     Document Type: Article

References (24)

1. Beijnen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol 2004 ; 5 : 489-96.
2. Corcoran ME. Polypharmacy in the older patient with cancer. Cancer Control 1997 ; 4 : 419-28.
3. Teil J, Henry A, Bossaert S, Charpiat B, Chekaoui A, Biron F, et al. Drug interactions between taxanes and antiretroviral agents : report of 2 cases. Fundament Clin Pharmacol 2006 ; 20 : 188 (abstract P259).
4. Schwartz JD, Howard W, Scadden DT. Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDS-related Kaposi's sarcoma. AIDS 1999 ; 13 : 283-4.
5. Bundow D, Aboulafia DM. Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with Aids-associated Kaposi sarcoma. Am J Clin Oncol 2004 ; 27 : 81-4.
6. Parameswaran R, Sweeny C, Einhorn L. Interaction between highly active antiretroviral therapy (HAART) and taxanes : a report of two cases. ASCO annual meeting 2002, abstract no 2194.
7. e édition. Paris : Edition Vidal, 2006.
8. er août 2006.
9. e édition.
10. er août 2006.
11. http ://www.ncbi.nlm.nih.gov/entrez/query.fcgi. Consulté le 10 octobre 2006.
12. Ikeda H, Murakami T, Takano M, Usui T, Kihira K. Pharmacokinetic interaction on valproic acid and recurrence of epileptic seizures during chemotherapy in an epileptic patient. Br J Clin Pharmacol 2005 ; 59 : 593-7.
13. Antoniou T, Tseng AL. Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 2005 ; 44 : 111-45.
14. De Maat MM, Ekhart GC, Huitema AD, Koks CH, Mulder JW, Beijnen JH. Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet 2003 ; 42 : 223-82.
15. Bower M, Powles T, Stebbing J, Thirlwell C. Potential antiretroviral drug interactions with cyclophosphamide, doxorubicin, and etoposide. J Clin Oncol 2005 ; 23 : 1328-9.
16. Martindale : the complete drug reference. Cederom, version 51. Pharmaceutical Press. Electronic version. Thomson Micromedex. Mise à jour de septembre 2005.
17. Lam M, Ignoffo R. A guide to clinically relevant drug interactions in oncology. J Oncol Pharm Pract 2003 ; 9 : 45-85.
18. Bower M, Palmieri C, Dhillon T. AIDS-related maligancies : changing epidemiology and the impact of highly active antirerroviral therapy. Curr Opin Infect Dis 2006 ; 19 : 14-9.
19. Lavole A, Wislez M, Antoine M, Mayaud C, Milleron B, Cadranel J. Lung cancer, a new challenge in the HIV-infected population. Lung Cancer 2006 ; 51 : 1-11.
20. Jansman FG, Jansen AJ, Coenen JL, de Graaf JC, Smit WM, Sleijfer DT, et al. Assessing the clinical significance of drug interactions with fluorouracil in patients with colorectal cancer. Am J Health Syst Pharm 2005 ; 62 : 1788-93.
21. Jansman FG, Idzinga FS, Smit WM, de Graaf JC, Coenen JL, Sleijfer DT, et al. Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer. Clin Ther 2005 ; 27 : 327-35.
22. Lee AH, Ingraham SE, Kopp M, Foraida MI, Jazieh AR. The incidence of potencial interactions between dietary supplements and prescription medications in cancer patients at a Veterans administration hospital, Am J Clin Oncol 2006 ; 29 : 178-82.
23. McCune JS, Hatfield AJ, Blackburn AA, Leith PO, Livingston RB, Ellis GK. Potential of chemotherapy-herb interactions in adult cancer patients. Support Care Cancer 2004 ; 12 : 454-62.
24. Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States : potential adverse interactions with anticancer agents. J Clin Oncol 2004 ; 22 : 2489-503.